Generation and evaluation of specific activity and authenticity of recombinant vaccine designed preventing against Pseudomonas aeruginosa

Cover Page


Cite item

Full Text

Abstract

The aim of the study was to obtain and characterize a recombinant vaccine for the immunoprophylaxis of infections caused by Pseudomonas aeruginosa. A set of two highly immunogenic P. aeruginosa recombinant proteins was used to create related vaccine. The first vaccine component was presented by recombinant outer membrane protein F (OprF), whereas the second one — by recombinant atoxic exotoxin A (toxoid). These antigens allowed to develop vaccine inducing immune response against the surface bacterial cues and promote production of neutralizing antibodies against exotoxin A, one of the most dangerous P. aeruginosa pathogenicity factors. Recombinant proteins were synthesized in Escherichia coli cells and isolated by two-step purification. In case of recombinant OprF protein, it was initially (stage 1) isolated as a precipitate containing hydrophobic fraction of producer cell-derived proteins, whereas for recombinant toxoid we purified inclusion bodies. At stage 2, a Ni Sepharose column affinity chromatography was performed. Next, purified recombinant proteins were dialyzed against buffer solution containing 50 mМ Tris-HCl (pH 9.0) and 0.01% Tween 20 followed by filtration sterilization. Three lots of the Pseudomonas Recombinant Vaccine (PRV) were obtained for the study, wherein the recombinant antigens were absorbed with aluminum hydroxide. Recombinant OprF and toxoid protein in vaccine formula were used at a dose of 25 μg and 50 μg, respectively. Absorption completeness of the recombinant antigens within the vaccine was evaluated by polyacrylamide gel electrophoresis with PRV preparations concentrated by ultrafiltration in spin columns. Authenticity of recombinant vaccine was assessed by using customized method by desorbing antigens followed by ultrafiltration concentration in spin columns. Final concentrated desorbed vaccine preparations were analyzed by polyacrylamide gel electrophoresis and immunoblotting, which allowed to confirm presence of specific recombinant antigens in the vaccine. The experimental PRV series demonstrated specific activity (protective properties) after inoculation in animals (mice) by using a dual vaccination protocol, wherein mice were immunized intraperitonially twice with a two-week interval. Next, two weeks later mice were infected by toxigenic P. aeruginosa strain PA-103 culture cells. The index of protective efficiency (IE) for experimental vaccine series was at least a value of three (IE: 3.0–3.3) that was by 1.5-fold higher than that for using single vaccine components (IE: 2.0–2.3). Thus, we confirmed an additive effect of using a set preparation to protect against infection caused by toxigenic Pseudomonas aeruginosa strains.

About the authors

A. A. Kaloshin

Mechnikov Research Institute of Vaccines and Sera

Author for correspondence.
Email: alex-k-1973@yandex.ru
ORCID iD: 0000-0001-8679-2421

Alexei A. Kaloshin,  PhD (Biology), Leading Researcher, Laboratory of Protective Antigens 

105064, Moscow, Malyi Kazennyi lane, 5А

Phone: +7 (965) 136-51-45 (mobile), 8 (495) 916-25-87 (office)

Fax: +7 (495) 917-54-60 

Россия

E. M. Zimina

Mechnikov Research Institute of Vaccines and Sera

Email: ziminka@ya.ru
ORCID iD: 0000-0003-2167-8905

Junior Researcher, Laboratory of Protective Antigens

Moscow 

 

Россия

E. O. Kalinichenko

Mechnikov Research Institute of Vaccines and Sera

Email: gladius.domini@gmail.com
ORCID iD: 0000-0002-0048-3968

PhD Student, Junior Researcher, Laboratory of Mechanisms of Immunity Regulation

Moscow 

Россия

N. A. Mihailova

Mechnikov Research Institute of Vaccines and Sera

Email: n_michailova@inbox.ru
ORCID iD: 0000-0002-6652-2093

PhD, MD (Medicine), Head of the Laboratory of Protective Antigens

Moscow 

Россия

References

  1. Благовидов Д.А., Костинов М.П., Симонова О.И., Шмитько А.Д., Буркина Н.И., Шахназарян М.К. Переносимость вакцины против P. aeruginosa у детей с муковисцидозом и врожденными пороками развития легких // Эпидемиология и вакцинопрофилактика. 2016. Т. 15, № 2 (87). С. 55–66. [Blagovidov D.A., Kostinov M.P., Simonova O.I., Shmit’ko A.D., Burkina N.I., Shahnazaryan M.K. The tolerability of the vaccine against P. aeruginosa in children with cystic fibrosis and congenital lung development. Jepidemiologija i vakcinoprofilaktika = Epidemiology and Vaccinal Prevention, 2016, vol. 15, no. 2, pp. 55–66. (In Russ.)] doi: 10.31631/2073-3046-2016-15-2-55-66
  2. Калошин А.А., Леонова Е.И., Солдатенкова А.В., Михайлова Н.А. Исследование протективных свойств комплекса рекомбинантного белка F наружной мембраны и рекомбинантного анатоксина Pseudomonas aeruginosa // Вестник Российской академии медицинских наук. 2016. Т. 71, № 1. С. 17–22. [Kaloshin A.A., Leonova E.I., Soldatenkova A.V., Mikhailova N.A. Assessment protective properties of the recombinant complex of the outer membrane protein F and the toxoid of Pseudomonas aeruginosa. Vestnik Rossiiskoi akademii meditsinskikh nauk = Herald of the Russian Academy of Sciences, 2016, vol. 71, no. 1, pp. 117–122. (In Russ.)] doi: 10.15690/vramn584
  3. Лазарева А.В., Чеботарь И.В., Крыжановская О.А., Чеботарь В.И., Маянский Н.А. Pseudomonas aeruginosa: патогенность, патогенез и патология // Клиническая микробиология и антимикробная химиотерапия. 2015. Т. 17, № 3. С. 170–186. [Lazareva A.V., Chebotar I.V., Kryzhanovskaya O.A., Chebotar V.I., Mayanskiy N.A. Pseudomonas aeruginosa: pathogenicity, pathogenesis and diseases. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy, 2015, vol. 17, no. 3, pp. 170–186. (In Russ.)]
  4. Макаренко Т.А., Станиславский Е.С. Иммунологическое изучение белков клеточной стенки Pseudomonas aeruginosa // Журнал микробиологии, эпидемиологии и иммунобиологии. 1996. № 2. C. 7–9. [Makarenko T.A., Stanislavskiĭ E.S. An immunological study of the cell-wall proteins of Pseudomonas aeruginosa. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology, 1996, no. 2, pp. 7–9. (In Russ.)]
  5. Патент № 1481962 С Российская Федерация, МПК. A61K 35/74. Способ обезвреживания очищенного экзотоксина А синегнойной палочки; заявлено 1987.07.15: опубликовано 1995.09.06 / Михайлова Н.А., Шаймухаметов Ф.А., Кузнецова Т.Н., Мороз А.Ф. Патентообладатель: УфНИИВС им. И.И. Мечникова, ГУ НИИЭМ им. Н.Ф. Гамалеи. 3 с. [Patent No. 1481962 С Russian Federation, Int. Cl. A61K 35/74. Method for rendering harmless exonoxin A of Pseudomonas aeruginosa; application: 1987.07.15: date of publication 1995.09.06 / Mikhailova N.A., Shajmukhametov F.A., Kuznetsova T.N., Moroz A.F. Proprietors: Ufimskij nauchnoissledovatel’skij institut vakcin i syvorotok im. I.I.Mechnikova (UfNIIVS im. I.I. Mechnikova), Nauchno-issledovatel’skij institut jepidemiologii i mikrobiologii im. N.F. Gamalei (GU NIIEM im. N.F. Gamalei). 3 p.]
  6. Подгорная Л.Г., Дзюбан Н.Ф. Антигенные свойства анатоксина синегнойной палочки и протективное действие антитоксической противосинегнойной сыворотки // Журнал микробиологии, эпидемиологии и иммунобиологии. 1986. № 6. С. 67–69. [Podgornaia L.G., Dziuban N.F. Antigenic properties of Pseudomonas aeruginosa anatoxin and the protective action of antitoxic anti-Pseudomonas aeruginosa serum. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology, 1986, no. 6, pp. 67–69. (In Russ.)]
  7. Станиславский Е.С., Йоо И., Северцева М.К., Машилова Г.М., Болтуцкий Л.Г. Иммунологическая эффективность и безвредность в эксперименте пиоиммуногена-вакцины против инфекции Pseudomonas aeruginosa // Журнал микробиологии, эпидемиологии и иммунобиологии. 1982. № 5. С. 70–75. [Stanislavskiĭ E.S., Joó I., Severtsova M.K., Mashilova G.M., Boltutsiĭ L.G. Experimental immunological effectiveness and safety of pyoimmunogen vaccine against Pseudomonas aeruginosa infection. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology, 1982, no. 5, pp. 70–75. (In Russ.)]
  8. Титова Т.И., Сидорова Т.Н., Радкевич С.А., Анциферова Н.Г., Мороз А.Ф. Получение и изучение свойств поливалентной корпускулярной синегнойной вакцины // Журнал микробиологии, эпидемиологии и иммунобиологии. 1985. № 8. С. 80–88. [Titova T.I., Sidorova T.N., Radkevich S.A., Antsiferova N.G., Moroz A.F. Production and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology, 1985, no. 8, pp. 80–88. (In Russ.)]
  9. Фармакопея.рф: сайт о регистрации лекарственных средств в России. Общая фармакопейная статья ОФС.1.2.4.0003.15 Стерильность. [Pharmacopoeia.ru: site about registration of drugs in Russia and EAEU (CIS). General pharmacopoeia monograph GPM.1.2.4.0003.15 Sterility]. URL: https://pharmacopoeia.ru/ofs-1-2-4-0003-15-sterilnost-3 (10.12.2019)
  10. Chatterjee M., Anju C.P., Biswas L., Mohan G., Biswas R. Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int. J. Med. Microbiol., 2016, vol. no. 1, pp. 48–58. doi: 10.1016/j.ijmm.2015.11.004
  11. Döring G., Pier G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine, 2008, vol. 26, no. 8, pp. 1011– 1024. doi: 10.1016/j.vaccine.2007.12.007
  12. Kaloshin A.A., Gatypova E.V., Mikhailova N.A. Obtaining recombinant forms of the outer membrane protein F of Pseudomonas aeruginosa and assessment of their immunogenic properties. Appl. Biochem. Microbiol., 2011, vol. 47, no. 8, pp. 780–788. doi: 10.1134/S0003683811080060
  13. Kaloshin A.A., Isakov M.A., Mihailova N.A., Vertiev Ju.V. Preparation of recombinant atoxic form of exotoxin a from Pseudomonas aeruginosa. Bull. Exper. Biol. Med., 2013, vol. 154, no. 3, pp. 346–350. doi: 10.1007/s10517-013-1947-1
  14. Lee N.G., Jung S.B., Ahn B.Y., Kim Y.H., Kim J.J., Kim D.K., Kim I.S., Yoon S.M., Nam S.W., Kim H.S., Park W.J. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Vaccine, 2000, vol. 18, no. 18, pp. 1952–1961. doi: 10.1016/S0264-410X(99)00479-X
  15. Sambrook J.F., Russell D.W. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press, 2001. 2100 p.
  16. Shanmugham R., Thirumeni N., Rao V.S., Pitta V., Kasthuri S., Singanallur N.B., Lingala R., Mangamoori L.N., Villuppanoor S.A. Immunocapture enzyme-linked immunosorbent assay for assessment of in vitro potency of recombinant hepatitis B vaccines. Clin. Vaccine Immunol., 2010, vol. 17, no. 8, pp. 1252–1260. doi: 10.1128/CVI.00192-10

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Kaloshin A.A., Zimina E.M., Kalinichenko E.O., Mihailova N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies